Unlock better outcomes with real-world closed claims data from taXonomy
As high-value therapies become the new norm,life sciences teams need closed claims data that...
How the FDA is using real-world evidence in safety and approval decisions
Regulatory decision-making depends on evidence that reflects how medical products perform in real-world use, not only in controlled trials. For more than a decade, the Food and Drug Administration has relied on real-world data and real-world...
The biomarker advantage
HealthVerity COO Andrew Goldberg recently sat down with Quest Diagnostics’ Director, Health...
Open claims vs. closed payer claims: What’s the difference?
Open claims and closed payer claims data are essential for understanding the status and activities...
Manageable medical device monitoring with real-world data
The FDA often requires some sort of post-market surveillance for medical devices to determine the...
Mastering precision, not indecision in real-world data
Real-world data (RWD) offers a multitude of use cases that can benefit pharmaceutical companies...
Enhancing go-to-market strategies with real-world data
Our series exploring the value of real-world data (RWD) throughout the pharmaceutical product life...
Extending value long after the clinical trial with real-world data
In our ongoing series, we have been discussing the value of real-world data (RWD) throughout the...
Honoring MOM: How far we've come
Two years ago, HealthVerity launched the Maternal Outcomes Masterset (MOM) to address the...
Three key elements to improve physician outreach
Historically, pharmaceutical manufacturers leveraged retail pharmacy prescriptions to identify...
Using Real-World Data to Power Government Health Messaging
The COVID-19 pandemic illustrated how vital government communications can be for effective public...